Ligand Pharma (LGND) Tops Q4 EPS by 17c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.47 -1.65%
EPS Growth %: -24.9%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: -24.9%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $50.5 million versus the consensus estimate of $47.82 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
